Stockwinners Market Radar for January 23, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:04 EST Cathie Wood's ARK Investment bought 73.2K shares of Teladoc today

20:03 EST Cathie Wood's ARK Investment bought 13.2K shares of Tesla today

19:57 EST Gatos Silver extends deeps zone at Cerro Los Gatos - Gatos Silver "provided a quarterly update on the drilling and exploration programs in the Los Gatos district, including the extension of the South-East Deeps zone at its 70%-owned Cerro Los Gatos mine. The Company also announced a corporate update regarding the timeline for filing outstanding financial statements."

18:57 EST Southwest dispatch staff reaches tentative agreement on contract - The company states: "Southwest Airlines and the Transport Workers Union Local 550 announced they reached a Tentative Agreement for the airline's Dispatch Employees. This Tentative Agreement covers Southwest's more than 450 Flight Dispatchers, Assistant Dispatchers, Flight Superintendents, Dispatch Specialists, and Dispatch ATC Specialists. The TWU 550 will share details directly with its members about the agreement and the voting process."

18:17 EST Toast CEO sells $3.15M in common stock - In a regulatory filing, Toast disclosed that its CEO Christopher Comparato sold 162.3K shares of common stock on January 19th in a total transaction size of $3.15M.

18:04 EST Amazon Web Services launches second infrastructure region in Australia - Amazon Web Services announced the launch of its second AWS infrastructure Region in Australia-the AWS Asia Pacific (Melbourne) Region. Starting today, developers, startups, entrepreneurs, and enterprises, as well as government, education, and nonprofit organizations, will have greater choice for running their applications and serving end users from AWS data centers located in Australia. AWS is planning to invest an estimated $4.5 billion (approx. A$6.8 billion) in Australia by 2037 through the AWS Asia Pacific (Melbourne) Region. "Australia has a strong history of technical innovation, and the launch of a second AWS Region in Australia provides even greater resilience and enables more customers to develop cloud-based applications that help fuel economic development across the country," said Prasad Kalyanaraman, vice president of Infrastructure Services at AWS. "The AWS Asia Pacific (Melbourne) Region adds to our ongoing infrastructure expansion and investments in Australia since we launched the AWS Asia Pacific (Sydney) Region in 2012. We are proud to deepen our investment by driving local job creation, building cloud skills, and creating opportunities for growth and collaboration with our local customers and AWS Partners."

17:45 EST Amazon and payment platform Stripe in expanded global pact - Payment processing platform Stripe blogged in part earlier: "Amazon and Stripe sign an expanded global agreement, deepening the two companies' long-standing partnership. Under the new agreement, Stripe will become a strategic payments partner for Amazon in the US, Europe, and Canada, processing a significant portion of Amazon's total payments volume across its businesses, including Prime, Audible, Kindle, Amazon Pay, Buy With Prime, and more... Stripe will expand its use of Amazon Web Services, Stripe's long-standing cloud infrastructure provider, to run and grow its business while reliably serving millions of internet companies. Though Stripe and Amazon have worked closely together for more than a decade, today's partnership announcement marks a new chapter in the two companies' enduring relationship. "Stripe has been a trusted partner, helping accelerate our business at every turn," said Max Bardon, vice president of payments, Amazon. "In particular, we value Stripe's reliability. Even during peak days like Prime Day, Black Friday, and Cyber Monday, Stripe delivers industry-leading uptime. We appreciate Stripe's relentless commitment to putting users first." Reference Link

17:17 EST Four Corners Property Trust names James Brat as COO - Four Corners Property Trust "announced that it has promoted James Brat to serve as FCPT's Chief Operations Officer. Mr. Brat joined FCPT at its inception in November 2015 as General Counsel and was promoted to Chief Transaction Officer in January 2020."

17:13 EST Rockley Photonics Holdings trading halted, news pending

17:02 EST Independent Bank authorizes up to $125M share repurchase - Independent Bank said that its Board of Directors additionally authorized the company to repurchase up to $125M of its outstanding common stock through December 31, 2023, at the discretion of management.

16:43 EST Citizens Bank names Stacy Brantley as next CEO - The Citizens Bank, wholly owned subsidiary of Citizens Holding Company, has hired Stacy M. Brantley as its next CEO. He will join the bank in February. Prior to joining The Citizens Bank, Brantley served as Executive Vice President and Chief Banking Officer for Morris Bank of Georgia where he oversaw all lending and branch sales.

16:41 EST Ford sees Q4 pre-tax remeasurement gain of roughly $50M from pension, OPEB plans - In a regulatory filing, Ford said: "We expect to record a pre-tax remeasurement gain in our fourth quarter 2022 results of approximately $50 million related to our pension and OPEB plans. This includes a $1.7 billion loss associated with pension plans in the United States, a $450 million gain associated with pension plans outside the United States, and a $1.3 billion gain associated with OPEB plans globally. Overall, the small remeasurement gain is primarily explained by higher discount rates compared with year-end 2021 largely offset by pension asset returns that were lower than our assumptions. On an after-tax basis, the remeasurement is expected to decrease our net income by about $220 million. The decrease is due to the net deferred tax expense we expect to recognize as a result of the variability in tax rates in the jurisdictions where there are remeasurement gains or losses. Because the remeasurement is a special item, it will not impact our total Company adjusted EBIT or adjusted earnings per share. The remeasurement did not have an impact on our cash in 2022, and does not change our expectations for pension contributions in 2023. In aggregate, our funded plans remain fully funded. Including the impact of remeasurement gains and losses during 2022, we expect the underfunded status for our pension and OPEB plans to be about $0.2 billion and $4.5 billion, respectively, at year-end 2022, compared with $0.3 billion and $6.0 billion, respectively, at year-end 2021. The change to the underfunded status of our plans in the aggregate primarily reflects the impact of higher discount rates."

16:33 EST Delek Logistics raises dividend 3% to $1.02 - Delek Logistics Partners declared its quarterly cash distribution for the Q4 of $1.02 per common limited partner unit, or $4.08 per common limited partner unit on an annualized basis. This distribution represents a 3% increase from the distribution for the Q3 of 99c per common limited partner unit and a 5% increase over Delek Logistics' distribution for the Q4 of FY21 of 97.5c per common limited partner unit. The fourth quarter 2022 cash distribution is payable on February 9 to unitholders of record on February 2.

16:31 EST HighPeak Energy initiates process to evaluate strategic alternatives - HighPeak Energy announced that its board of directors has voted to initiate a process to evaluate certain strategic alternatives to maximize shareholder value, including a potential sale of the company. HighPeak chairman and CEO, Jack Hightower, released the following statement: "The Board and I believe now is an opportune time to capture the value we do not consider is presently reflected in our share price. We have worked diligently over the last few years to secure this position and are poised to capitalize on the favorable energy market outlook. Many investors remain unfamiliar with the extent of de-risking that has occurred in the Eastern Howard County area of the Midland Basin. There are currently 11 oil and gas companies running 21 rigs in Howard County, with over 1,600 completions in the last three years. HighPeak successfully drilled 215 horizontal wells across the Wolfcamp and Spraberry formations since inception. Furthermore, set against an economic backdrop of increasing scarcity of premium undeveloped inventory in the Permian Basin, HighPeak has identified approximately 2,500 total locations, including approximately 1,300 delineated primary locations which have a projected average return of 95% at a flat price of $90/Bbl WTI and $4/MMBtu HH natural gas. Our production is over 90% liquids and, based on public data, our margins are the highest of any pure-play Permian Basin public company. Our primary inventory locations alone are expected to provide over 14 years of activity at a 4-rig pace, which is what we project will be needed to maintain our estimated 2024 production level of around 75,000 Boe per day. We believe our current acreage position of approximately 110,000 acres, consisting of two highly contiguous blocks, is configured optimally for efficient development. From the beginning, we had the long-term goal to both develop this acreage to maximize our returns and to minimize future infill, parent-child related issues. We have planned our facilities, infrastructure, and production corridors in an environmentally sound, efficient manner and consider our asset base, with its many years of high return inventory and first-class infrastructure and production facilities, as one of the premier acreage positions in the Midland Basin. Based on our forecast, we anticipate having self-sustaining operations and becoming cash flow positive in the second half of this year and then transitioning into consistent free cash flow generation thereafter. We believe we are currently trading at a substantial discount to our intrinsic value and our investors will benefit materially as we transition into a free cash flow mode. Likewise, we believe many companies would benefit from owning our portfolio to extend their premium inventory life and enhance their return on capital. Due to our deep, high return inventory, industry leading margins, and long-term free cash flow generating asset base, we believe that our share price should move up to the trading multiples currently realized by certain potential purchasers and large cap pure play owners of Midland Basin assets. In closing, the Board and I are excited to start this process to explore ways to maximize the Company's value for all its shareholders."

16:30 EST Entegris CFO Greg Graves to retire in 2023 - Entegris "announced that Greg Graves, executive vice president and chief financial officer, plans to retire in 2023. The company has initiated a search to identify its next CFO with the assistance of a leading executive search firm and will consider both internal and external candidates. Graves will continue to serve as CFO until his successor is appointed and is expected to remain with the company through a transition period."

16:19 EST Ocwen board elects CEO Glen Messina as board chair - Ocwen announced that its board of directors has unanimously elected Glen Messina as chair of the board, effective January 23. Messina will continue to serve as president and CEO of Ocwen, a position he has held, along with serving on the board as a director, since October 2018. Messina succeeds Phyllis Caldwell, who has successfully served as chair since March 2016 and as a director since January 2015. Caldwell will remain on the board as an independent director and intends to stand for re-election at the next annual meeting.

16:16 EST Hess Midstream Partners raises quarterly dividend by 1.2% to 57c per share - The distribution will be payable on February 13, 2023 to shareholders of record as of the close of business on February 2, 2023.

16:15 EST Capri Holdings names Cedric Wilmotte CEO of Michael Kors - Capri Holdings announced that Cedric Wilmotte will be appointed Chief Executive Officer of the Michael Kors brand effective April 3, 2023. Wilmotte recently served as the interim Chief Executive Officer for Versace from January through September 2022 and is currently Versace's Chief Operating Officer. Prior to his time at Versace, Mr. Wilmotte led the Michael Kors EMEA business from its inception in 2008 through 2021. During his tenure as President of Michael Kors EMEA, Mr. Wilmotte was responsible for Michael Kors' significant growth in the region. Before joining Michael Kors, Mr. Wilmotte held senior leadership positions at Marc Jacobs in Paris from 2004 to 2008 and at Donna Karan in New York, London and Milan from 1998 to 2004. John D. Idol, Chairman and Chief Executive Officer of Capri Holdings said, "I am thrilled to welcome Cedric back to the Michael Kors team as our new Chief Executive Officer. Cedric is a strong leader with extensive retail and merchandising experience and has a deep understanding of the Michael Kors brand and consumer."

16:14 EST Zions Bancorp reports Q4 net interest income up 30% y/y at $720M - Reports Q2 net interest margin 3.53% vs. 2.58% y/y

16:11 EST Moving iMage names William Greene interim CFO - Moving iMage Technologies named William "Bill" Greene as interim chief financial officer, effective immediately. Greene brings an extensive background in public accounting, SEC reporting, capital raising, M&A due diligence and internal controls working as a CFO, Big 8 auditor and financial consultant for both public and private companies. Greene holds a B.S. in Business Administration, with a concentration in Accounting from the California State University - Dominguez Hills.

16:10 EST Intel names Frank Yeary new independent chair - Intel Corporation announced that Frank D. Yeary has been appointed as the new independent chair of its board of directors. This follows Dr. Omar Ishrak's decision to step down as chair. Ishrak will remain on Intel's board as an independent director and continue to serve on the audit and finance committee and corporate governance and nominating committee. "I'm pleased to welcome Frank as chair of Intel's board. His expertise in unlocking stockholder value, focus on corporate governance and familiarity with Intel are powerful assets to both the board and the company as we execute our strategy," said Pat Gelsinger, CEO of Intel. "I also want to thank Omar for his tremendous contributions as chair. He was instrumental in bringing me back to the company as CEO and has fostered a high-impact working dynamic across the board and management team. I look forward to his continued service as a valued member of the board."

16:07 EST Simmons First National declares quarterly dividend of 20c per share - Payable on April 3 to shareholders of record as of March 15. The cash dividend rate represents an increase of 1c per share, or 5%, from the dividend paid for the same time period last year.

15:00 EST Sumo Logic up 25% after Information's report on PE approaches - Shares of Sumo Logic are up $1.90, or 25%, to $9.57 in afternoon trading following the report regarding private equity interest.

14:50 EST Sumo Logic trading halted, volatility trading pause

14:09 EST Association of Pickleball Professionals announces broadcast deals with CBS, ESPN - The Association of Pickleball Professionals, or APP, has announced deals with CBS Sports (PARA) and ESPN (DIS) to deliver hundreds of hours of APP Tour pickleball programming throughout 2023, including 12 hours of live matches and highlight-driven programs on CBS Sports Network, eight hours of event recap telecasts on ESPN2 and more than 200 hours of live streaming coverage on ESPN+ and APP TV. Reference Link

13:37 EST Catalyst comments on the FDA's position on orphan drug exclusivity - Catalyst Pharmaceuticals (CPRX) commented on the FDA's notice setting forth its position on Orphan Drug Exclusivity in light of the 11th Circuit's decision in Catalyst Pharmaceuticals, Inc. v. Becerra, stating: "The FDA announcement states that while the FDA is complying with the 11th Circuit decision in Catalyst's favor with respect to FIRDAPSE, the FDA intends to continue to apply its regulations tying the scope of orphan drug exclusivity to the uses or indications for which a drug is approved with respect to other orphan drugs. Catalyst reports that it is not affected by the FDA's newly announced position and that the FDA's announcement confirms the FDA's previous decision to set aside the approval of RUZURGI as a result of the 11th Circuit's decision. Further, Catalyst acquired the United States rights to RUZURGI, including all intellectual property relating thereto, in July 2022. Finally, Catalyst's supplemental New Drug Application expanding its label for FIRDAPSE to children ages 6-17 was approved by the FDA in September 2022." Separately, Catalyst announced this morning that an abbreviated new drug application has been filed by Teva Pharmaceuticals (TEVA), seeking authorization from the FDA to manufacture, use, or sell a generic version of FIRDAPSE in the United States. "As Catalyst has previously reported, the filing of a Paragraph IV challenge to FIRDAPSE was not unexpected, and Catalyst intends to vigorously enforce its intellectual property rights relating to FIRDAPSE," the company stated.

13:07 EST Signature Bank says it does not lend in the crypto space - In response to a Wall Street Journal article, the company said, "The headline falsely refers to Signature Bank as a 'crypto lender.' Signature Bank does not lend in the crypto space, nor does it have loans that are backed by crypto assets. Additionally, the Bank does not invest, does not hold, and does not custody crypto assets. Signature Bank's relationships with clients in the crypto space are limited to U.S. dollar-denominated deposits only."

12:56 EST KULR Technology CEO says 'time to stand up to naked short selling' - KULR Technology CEO Michael MO said in a tweet that, "It's time to stand up to naked short selling. It's predatory and it's illegal. We must do everything to ensure the health of publicly traded markets. Looking forward to seeing how the $HLBZ and $GNS investigations progress. #NakedShortWar" Reference Link

12:26 EST Ballard Power announces order from CrossWind to supply fuel cell system - Ballard Power Systems (BLDP) announced an order for a fuel cell system to CrossWind, a joint-venture between Shell (SHEL) and Eneco. The Ballard fuel cell system will be integrated in the Hollandse Kust Noord offshore wind project. The Hollandse Kust Noord offshore wind project, located off the coast of the Netherlands, will have a capacity of 759 MW to generate at least 3.3 TWh per year. This is enough renewable power to supply the equivalent of more than 1 million Dutch households with green electricity. CrossWind intends to use various new technologies to manage the intermittent wind power generation, including the use of water electrolysis to convert wind power into green hydrogen for energy storage. Ballard's hydrogen fuel cells will utilize the green hydrogen as fuel to regenerate stable and dispatchable power. Ballard will supply a containerized fuel cell power solution with a peak power capacity of 1 MW, with delivery expected in 2024.

12:00 EST Direxion Daily Semiconductor Bear 3X Shares falls -12.5% - Direxion Daily Semiconductor Bear 3X Shares is down -12.5%, or -$3.54 to $24.74.

12:00 EST Direxion Daily Semiconductor Bull 3X Shares rises 12.9% - Direxion Daily Semiconductor Bull 3X Shares is up 12.9%, or $1.65 to $14.44.

12:00 EST Wayfair rises 25.3% - Wayfair is up 25.3%, or $11.83 to $58.62.

11:39 EST Boise Cascade plans door shop facility in Kansas City - Boise Cascade Company announced the planned addition of its 10th door shop. Located in Kansas City, this new 150,000 sq. ft. millwork facility is expected to begin production in June 2023. Boise Cascade's Building Materials Distribution division currently operates nine millwork manufacturing and distribution locations offering pre-hung doors and other products in some of the country's fastest growing markets. The Company will continue to partner with brands such as Therma-Tru featuring Tru-Guard Composite Technology as well as PrismaGuard premium finishing options, Simpson wood doors, and Steves & Sons interior doors.

11:00 EST Vericity Inc trading resumes

10:46 EST Pitney Bowes comments on Hestia Capital's actions - Pitney Bowes acknowledged receipt of Hestia Capital's notice of nomination of seven director candidates, constituting a majority slate of director candidates, to the Pitney Bowes Board of Directors in connection with the Company's upcoming annual meeting of shareholders. Pitney Bowes said: "Consistent with its fiduciary duty to shareholders and the Company's governing documents, the Board will review any properly noticed nominations in due course. Shareholders are not required to take any action at this time. The Board and management team have engaged in an open and good faith dialogue with Hestia over many months. Contrary to Hestia's assertion, Pitney Bowes is always interested in considering well-qualified candidates to join the Board. Moreover, the Board offered to appoint two candidates proposed by Hestia to the Board in December. However, Hestia was unwilling to reach a reasonable compromise. Instead, both their current and prior public announcements demonstrate that they are more interested in fighting than in engaging in constructive conversations to benefit all shareholders, not just themselves. Furthermore, throughout discussions with Hestia, they demonstrated a fundamental misunderstanding of the Company and have failed to articulate a strategy that would justify ceding control of the Company to them. Pitney Bowes will continue to seek the right path forward that is in the best interests of all shareholders, including potential additions of well qualified candidates to the Board of Directors. The Company will not let Hestia's unwillingness to seek common ground stand in the way."

10:26 EST Integral Ad Science appoints Kevin Alvero as head of global compliance - Integral Ad Science announced the appointment of Kevin Alvero as Head of Global Compliance, effective immediately. Alvero will lead the global accreditation process and manage compliance worldwide for IAS. Prior to joining IAS, Alvero was Senior Vice President, Internal Audit, Compliance, and Governance at Nielsen Holdings.

10:17 EST Community Heritage raises quarterly dividend 50% to 6c per share - Community Heritage Financial announced its Board of Directors declared a quarterly cash dividend on its common stock of 6c per share. This represents an increase of 50% from the previous quarterly dividend of 4c per share. The dividend is payable on February 10, 2023 to shareholders of record on February 3, 2023.

10:00 EST Xylem falls -9.9% - Xylem is down -9.9%, or -$10.88 to $99.31.

10:00 EST Gaotu Techedu rises 11.3% - Gaotu Techedu is up 11.3%, or 43c to $4.22.

10:00 EST Wayfair rises 25.4% - Wayfair is up 25.4%, or $11.88 to $58.67.

09:50 EST Benitec Biopharma enrolls first OPMD subject into clinical development program - Benitec Biopharma announced the enrollment of the first oculopharyngeal muscular dystrophy patient into the OPMD natural history phase of the BB-301 clinical development program. The OPMD Natural History Study represents the 6-month pre-treatment observation period for each OPMD subject prior to the administration of BB-301 for the treatment of OPMD-related dysphagia. Upon the completion of 6-months of radiographic and clinical assessments required for the NH Study, participants will be eligible for enrollment into the BB-301 Phase 1b/2a treatment study in which BB-301 will be administered. The OPMD NH Study will facilitate the characterization of OPMD patient disposition at baseline and assess subsequent rates of progression of dysphagia via the use of the following quantitative radiographic measures, with the VFSS outlined below collectively providing objective assessments of swallowing safety, swallowing efficiency, and the functional capacity of the specific pharyngeal constrictor muscles underlying the progression of dysphagia in OPMD patients: Total Pharyngeal Residue %; Pharyngeal Area at Maximum Constriction; Dynamic Imaging Grade of Swallowing Toxicity Scale; Vallecular Residue %, Pyriform Sinus Residue %, and Other Pharyngeal Residue; Normalized Residue Ratio Scale; Pharyngeal Construction Ratio. The NH study will also employ clinical measures of global swallowing capacity and oropharyngeal dysphagia, along with two distinct patient-reported outcome instruments targeting the assessment of oropharyngeal dysphagia. Upon the achievement of 6-months of follow-up in the NH Study, participants will be eligible for enrollment into the planned BB-301 Phase 1b/2a treatment study.

09:47 EST Eve Holding falls -8.6% - Eve Holding is down -8.6%, or -63c to $6.71.

09:47 EST IAA rises 6.6% - IAA is up 6.6%, or $2.68 to $43.33.

09:47 EST Wayfair rises 18.8% - Wayfair is up 18.8%, or $8.81 to $55.60.

09:44 EST TGI Solar Group to acquire Shelly North Carolina, terms not disclosed - TGI Solar Power Group announced the closing of its business combination with Shelly North Carolina, Inc. Shelly AI solutions empower companies to be more responsive, agile, and engaging with their customers, while dominating their markets and surpassing revenue projections. The two companies will look to finalize the deal as soon as the requisite due diligence reviews have been completed. As part of combination strategy Mr. Val will resign as TGI's CEO and Mr. Philippe Machuel, CEO of Shelly, will take over position of CEO of TGI as well as join the Board of Directors. Sara Machuel is going to be the the head of European Operation in Paris, France and in charge of global business development. As part of this reorganization strategy, TGI terminates its agreement with XR-LABS. The agreement is terminated, neither party will have any liability to the other except with respect to certain provisions of the agreement, such as confidentiality, governing law, interpretative and other provisions that are necessary to maintain the confidentiality of each party's information after agreement is terminated and to maintain the governing terms of the agreement in the event of a post termination dispute regarding the validity of termination itself.

09:27 EST GE HealthCare, Windsor Regional Hospital enter long-term MES agreement - Windsor Regional Hospital and GE HealthCare announced a 15-year Managed Equipment Service agreement to deliver innovative technology solutions and services to the communities WRH serves to help enable better patient outcomes, improve efficiencies for clinicians and staff, and expected significant cost savings to the hospital for years to come. This collaboration between GE HealthCare and the WRH clinical engineering team will provide system predictability and service resilience to help WRH deliver the future of healthcare. Through this agreement, GE HealthCare will take responsibility for the ongoing acquisition, installation, maintenance, and staff training for the majority of the medical technology utilized by WRH, including diagnostic imaging, surgical, cardiology and emergency department equipment, and more. This agreement is part of an emerging MES trend in Ontario hospitals, providing WRH with access to the most up-to-date medical technology at a predictable fee, along with regular performance reviews and product management.

09:24 EST SciSparc to investigate concerns of illegal trading of ordinary shares - SciSparc announced that its board of directors has decided to examine alternative measures to address concerns of illegal short sales of its ordinary shares. The Company believes that certain individuals and/or companies may have engaged in illegal short sale practices that have artificially depressed the Company's share price. As a result, SciSparc is evaluating several options and following the example of other public companies listed on Nasdaq and NYSE American like Helbiz, Inc. and Genius Group Ltd, and plans to retain third party professionals to review trading patterns of the Company's ordinary shares.

09:22 EST 22nd Century files U.S. DMF with FDA for CBD API - 22nd Century Group announced filing of a U.S. Drug Master File to the US Food & Drug Administration for cannabidiol API from GVB Biopharma, a 22nd Century Group Company. The company said, "The submission demonstrates 22nd Century Group's absolute commitment to supplying high quality pharmaceutical grade API to the pharmaceutical industry and OTC markets."

09:18 EST Ondas completes acquisition of Airobotics - Ondas Holding announced it has completed the previously announced acquisition of AIROBOTICS, an Israeli-based developer of autonomous unmanned aircraft systems and automated data analysis and visualization platforms, effective January 23, 2023. Pursuant to the definitive acquisition agreement, each issued and outstanding share of Airobotics was converted into, and exchanged for, 0.16806 shares of Ondas common stock. Ondas issued approximately 2.8 million shares as consideration to the Airobotics shareholders. As a result of the acquisition, the Company will be dual listed on Nasdaq and the Tel Aviv Stock Exchange. The first trading day of the Company's shares on TASE is expected to be January 26, 2023.

09:12 EST CACI awarded prime contract worth up to $284 M by NSA - CACI International announced that it has been awarded a single-award prime contract worth up to $284M by the National Security Agency NSA to provide mission expertise and systems engineering support for NSA's Cybersecurity Directorate. As the pace and scope of cybersecurity threats continue to increase, CACI's specialized expertise and knowledge in cybersecurity will help engineer solutions for some of our nation's most critical national security missions. Under the five-year contract, CACI will help to modernize NSA's systems engineering practices across their extended enterprise. John Mengucci, CACI President and Chief Executive Officer, said, "This award reflects CACI's ongoing commitment to support the NSA's critical missions. We appreciate the NSA's trust and confidence in our ability to find the right people with the right skills to protect these systems against an everchanging range of threats and to bring engineering solutions to reality."

09:11 EST Nano Dimension delivers 3D printer to Karlsruhe Institute of Technology - Nano Dimension announced that it has delivered the Admaflex130 Evolution, which is the first of its next generation high precision ceramics and metal fabrication system, to the Karlsruhe Institute of Technology.

09:10 EST Capital Power renews partnership with Art Gallery of Alberta - Capital Power has renewed its partnership with the Art Gallery of Alberta for the Capital Power Indigenous Art Fund which supports and celebrates Indigenous art and artists. In action of reconciliation, exhibitions, programming and free admission days will be provided for visitors to experience Indigenous culture and artistry at this world-class venue.

09:08 EST Evolus receives regulatory approval for Nuceiva in Australia - Evolus announced that the Australian Therapeutic Goods Administration TGA has provided regulatory approval for Nuceiva, prabotulinumtoxinA, a neurotoxin dedicated exclusively to aesthetics. Nuceiva was approved for the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients. Glabellar lines are the vertical lines between the eyebrows seen at maximum frown. "We are thrilled to gain regulatory approval for Nuceiva in Australia, one of the largest market opportunities for aesthetic neurotoxins outside of the United States, where we are rapidly gaining market share, and Great Britain, where we recently launched commercial operations," said David Moatazedi, President and Chief Executive Officer, Evolus. "This approval is the latest example of our commitment to broaden our international presence, which is a key component to reaching our aspiration of $500 million in total revenue by 2028." Evolus plans to launch Nuceiva in Australia during the second half of 2023 after commencing additional launches in Europe - beginning with Germany and Austria - in the first half of 2023. In addition to Great Britain, Nuceiv is also commercially available in Canada. The safety and efficacy of Nuceiva was evaluated through the company's global TRANSPARENCY clinical program, which included two Phase III U.S. trials, the largest head-to-head aesthetic pivotal study versus BOTOXor onabotulinumtoxinA to date, and two long-term safety studies. The product is approved for sale in the U.S. under the brand name Jeuveau.

09:07 EST LPL Financial welcomes new Linsco teams in Texas, Florida - LPL Financial LLC announced that two teams of financial advisors who serve a combined $275 million in advisory, brokerage and retirement plan assets have joined LPL's employee advisor channel, Linsco by LPL Financial. Chris Corcoran joins from Merrill Lynch and will be the first tenant in a new Linsco office in Houston, Texas. Additionally, Matt Jackson and Adam Callender join LPL from Truist and will work remotely from Northeast Florida.

09:06 EST Newell announces restructuring and savings initiative, to reduce headcount in Q1 - Newell Brands announced a restructuring and savings initiative, Project Phoenix. Project Phoenix is expected to be substantially implemented by the end of 2023. It incorporates a variety of initiatives to reduce overhead costs. In connection with Project Phoenix the company expects to realize annualized pre-tax savings in the range of $220M to $250M when fully implemented. Restructuring and related charges associated with these actions are estimated to be in the range of $100M to $130M and are expected to be substantially incurred by the end of 2023. The restructuring plan is expected to result in the elimination of approximately 13% of office positions. The company will begin reducing headcount in the first quarter 2023, with most of these actions expected to be completed by the end of 2023, subject to local law and consultation requirements. Newell Brands will implement a new operating model, consolidating its five operating segments into three operating segments. The company will combine its previously reported Commercial Solutions, Home Appliances and Home Solutions segments into one operating segment, Home & Commercial Solutions. Learning & Development and Outdoor & Recreation will remain as the company's other two operating segments. The company will report on this basis commencing January 1. Effective immediately, Kris Malkoski has been named the segment CEO for Learning & Development, Mike McDermott has been named the segment CEO for Home & Commercial Solutions, and Jim Pisani has been named segment CEO for Outdoor & Recreation. Dennis Senovich, chief supply chain officer, will lead the company's manufacturing, distribution, transportation and customer service functions globally. The company will provide additional details about Project Phoenix during its upcoming fourth quarter and full year 2022 earnings call on February 10.

09:06 EST Exagen elects Nova as Executive Chair of board of directors - Exagen (XGN) announced that Tina Nova, Ph.D. has been elected as Executive Chair of the Exagen Board of Directors, effective January 19, 2023. Dr. Nova succeeds Brian Birk, who has served as Chair of the Board of Directors at Exagen since 2018, and who will remain a member of the Board. Dr. Nova currently serves as President of Veracyte's (VCYT) U.S. CLIA business where she leads all aspects of the company's broad menu of diagnostic laboratory tests. Dr. Nova currently serves on the Board of Azenta (AZTA).

09:04 EST Eos Energy announces CFO Gonzales to step away, Kroeker to succeed - Eos Energy Enterprises announced that Randall Gonzales will be stepping away from his Chief Financial Officer, CFO, responsibilities into a corporate advisory role and will be succeeded by Nathan Kroeker, effective January 23, 2023. Kroeker brings 25 years of finance and energy industry experience. Kroeker spent 10 years at Spark Energy, starting as the CFO before eventually taking over as CEO in 2014.

09:02 EST eHealth appoints Ketan Babaria as Chief Digital Officer - eHealth appointed Ketan Babaria as SVP, Chief Digital Officer. Babaria joins eHealth from M1 Finance where he served as Chief Product Officer. Prior to M1 Finance, Mr. Babaria served as Chief Product Officer at Roofstock, Head of Product at LifeLock, and Sr. Director and Head of Product, D3 Incubation Unit at Capital One.

09:02 EST Argo Blockchain regains compliance with Nasdaq listing rule - Argo Blockchain announces that it has received a letter from the Listing Qualifications Department of The Nasdaq Stock Market informing the Company that it has regained compliance with Nasdaq Listing Rule 5450(a)(1). As announced on 16 December, 2022, Argo was notified by Nasdaq that its common stock had not maintained the minimum bid price of $1.00 over the previous thirty consecutive business days, as required by the Listing Rules of the Nasdaq Stock Market. To regain compliance, the Company was required to maintain a minimum closing bid price of $1.00 for ten consecutive trading days. This requirement was met on 13 January 2023. Accordingly, the company has regained compliance with Listing Rule 5450(a)(1), and Nasdaq has confirmed to the company that it considers this matter closed. Argo Blockchain shares are up 9% in pre-market at $1.88.

09:01 EST Arthur J. Gallagher acquires Remco Insurance Agencies - Arthur J. Gallagher's subsidiary, Risk Placement Services, has acquired Austin, Texas-based Remco Insurance Agencies. Terms of the transaction were not disclosed. Remco Insurance is a retail non-standard auto insurance agency serving clients throughout Texas. Rahim Peerbhai and his associates will remain in their current locations under the direction of Jorge Barcena, President of RPS Pronto.

08:52 EST Oaktree Specialty Lending completes merger with Oaktree Strategic Income II - Oaktree Specialty Lending announced the closing of the previously announced merger with Oaktree Strategic Income II, with OCSL as the surviving company. Based on December 31, 2022 financial information, the combined company has more than $3.3B of assets on a pro forma basis. In connection with the merger, former OSI II stockholders will receive 0.9115 shares of OCSL for each share of OSI II based on the final exchange ratio, subject to payment of cash in lieu of fractional shares. As a result of the merger, legacy OCSL stockholders and former OSI II stockholders own approximately 79.4% and 20.6%, respectively, of the combined company at closing. In addition, in connection with the closing of the merger, and as previously announced, OCSL and Oaktree Fund Advisers amended the existing investment advisory agreement to provide that Oaktree will waive $9M of OCSL's base management fees as follows: $6M at a rate of $1.5M per quarter in the first year following closing of the merger and $3M at a rate of $750,000 per quarter in the second year following closing of the merger.

08:47 EST NLS Pharmaceutics announces in-vitro data on Quilience - NLS Pharmaceutics announced new in vitro study results demonstrating the agonist effect of mazindol ER at the Orexin-2 Receptor. Two identical studies measuring differing concentrations of mazindol ER confirmed significant OX2R partial agonist activity at 30muM or higher. Notably, findings show that mazindol ER showed strong OX2R partial agonist activity by cellular and nuclear receptor functional assays. Results showed pEC50 values of 4.7 to 5 for mazindol on the OX2R, indicating a strong OX2R partial agonist. Orexin, also known as hypocretin, is a neuropeptide that regulates arousal, wakefulness, and appetite. Orexin plays a critical role in regulating the sleep-wake cycle and the most common form of narcolepsy, type 1, in which the individual experiences brief losses of muscle tone, known as or cataplexy, is caused by a lack of orexin in the brain due to destruction of the cells that produce it. Mazindol ER is an OX2R partial agonist that was developed to address the loss of orexin signaling in NT1. Currently available treatments for NT1 only address the associated symptoms but not the underlying loss of orexin. Additional pre-clinical in vivo studies are currently underway to confirm OX2R activity. A pilot study in OXR2 KO mice animal model compared favorably with investigational drug, TAK-925, an orexin 2 receptor agonist. Supplementary studies to further characterize OX2R activity as well as activity at OX1R are planned for the first half of 2023. NLS Pharmaceutics plans to present the study results at a scientific meeting later this year. The Phase 3 program for Quilience is currently on track to commence in mid- 2023.

08:45 EST 1847 Holdings provides update on special warrant dividend - 1847 Holdings provides an update on the previously announced issued dividend in the form of warrants to purchase the Company's common shares at $4.20 per common share. Ellery Roberts, CEO and Chairman of the Board of the Company, commented, "We believe that issuing this special warrant dividend to our loyal shareholders may help to expose those who may have participated in what we believe to be market manipulation relating to the Company's common shares. Through our engagement with ShareIntel, we are able to obtain share trading analytic metrics that are designed to better monitor trading activity. If you are a registered shareholder and have not received your warrants, please contact info@1847holdings.com. If you hold shares through a brokerage firm, bank, dealer or other similar organization, please reach out to your representative at such firm."

08:44 EST Jaguar Health announces board for JV Magdalena Biosciences - Jaguar Health announced that the board of directors has been established for Magdalena Biosciences, Inc., the joint venture recently formed by Jaguar and Filament Health. Magdalena board members include Jaguar Founder, President, and CEO Lisa Conte, Filament Co-Founder and CEO Benjamin Lightburn, and Jack Wielebinski, Fund Operating Officer, One Small Planet, LLC. Jaguar also announced that Dr. Karen Brunke, Jaguar's EVP of Corporate and Business Development, has been appointed acting CEO of Magdalena.

08:42 EST BriaCell to investigat alleged illegaltrading of public securities - BriaCell Therapeutic announced that it has approved measures to address alleged illegal trading activity of its publicly traded securities. The company said, "The Company believes that certain individuals and/or companies may have engaged in manipulative and/or suspected illegal trading practices that may have artificially depressed its share price. As a result, BriaCell is implementing a plan to address this issue which may include legal action. BriaCell is working to build one of the leading immuno-oncology companies in the biotech sector with a singular focus on commercializing our novel immunotherapy approach for cancer patients. While our clinical team remains dedicated to developing these desperately needed therapies, the Company recognizes that recent milestones have been achieved with the support of loyal investors who are instrumental in the ongoing development of our assets. By taking action to protect the interests of our shareholders, we are also protecting the interests of the Company and the tens of thousands of cancer patients in need of effective treatment options. To this end, BriaCell is pursuing avenues to address alleged illegal activities carried out by various parties potentially working collusively with the intent of depressing the Company's share price while undermining the interest of our shareholders."

08:41 EST Jupiter Wellness says reedemable digital coupons available for all shareholders - Jupiter Wellness announced their redeemable digital coupons are now available for shareholders of record to claim on Upstream's trading app. Upon a successful claim, shareholders may redeem the digital coupon for a gift package of company products valued at over $179 or trade the digital coupon with other fans globally on Upstream to bring new potential customers into the community. This news follows Jupiter Wellness's recent listing on Upstream on January 10, 2023. The gift package will include an assortment of CBD-infused products, including an 8oz Comfort Cream, 50 SPF CaniSun, 55 SPF CaniSun, 30 SPF CaniSun Continuous Spray, Acai Lip Balm, Peppermint Lip Balm, and their original Healing Lip Balm. In addition to the CBD products, investors will also receive a sample bottle of the company's NoStingz jellyfish prevention sunscreen. All shareholders of record as of December 30, 2022, will be entitled to claim the digital coupon.

08:39 EST Fortune Brands Innovations backs prior FY22 EPS view $6.20-$6.30 - Consensus estimate for FY22 EPS is $6.16. In advance of its fourth quarter and full-year earnings release, Fortune Brands is reaffirming the full-year 2022 sales growth and EPS guidance provided as part of its third quarter earnings release, which included the contribution of its Cabinets business for the full fiscal year. As stated in its third quarter earnings release, the Company expects 2022 full-year sales growth in the range of 4.5% to 5.5%, and EPS before charges / gains for the full year to be in the range of $6.20 to $6.30. The Company's complete fourth quarter and full-year results, as well as 2023 guidance, will be included in the fourth quarter earnings release, with more extensive commentary to follow during the quarterly investor call.

08:38 EST AlphaVest Acquisition announces separate trading of ordinary shares, rights - AlphaVest Acquisition Corp announced that, commencing January 25, 2023, holders of the 6,900,000 units sold in the Company's initial public offering, including the 900,000 units sold pursuant to the full exercise of the underwriters' over-allotment option, may elect to separately trade the ordinary shares and rights included in the units. Any units not separated will continue to trade on The Nasdaq Global Market under the symbol "ATMVU," and the separated ordinary shares and rights are expected to trade on the Nasdaq under the symbols "ATMV" and "ATMVR," respectively. Unitholders will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company's transfer agent, in order to separate the units into ordinary shares and rights. The units were initially offered by the Company in an underwritten offering. EarlyBirdCapital, Inc. acted as sole bookrunning manager of the offering and Revere Securities acted as co-manager of the offering. A registration statement relating to the units and the underlying securities was declared effective by the Securities and Exchange Commission on December 19, 2022.

08:37 EST CN Energy establishes U.S. headquarters for activated carbon businesses - CN Energy has established its U.S. headquarters in Washington D.C. to accelerate its biochar and wood-based activated carbon businesses in North and South America. CN Energy will collaborate with partners in the United States, Canada, Brazil, and Mexico to establish a marketing network to facilitate specific client needs. Both biochar and wood-based activated carbon have a range of applications in industrial manufacturing, pharmaceutical manufacturing, food and beverage production, and water purification. The 6th-generation gasification reactors of CN Energy are expected to be deployed on a larger scale in its production processes in 2023.

08:36 EST KULR Technology to demonstrate KULR VIBE products at 2023 VTOL Technical meeting - KULR Technology announced it will demonstrate its KULR VIBE suite of products and services at the 2023 Autonomous VTOL Technical Meeting and Electric VTOL Symposium on January 24-26, 2023 in Mesa, Arizona. KULR is a sponsor of the event, which is in its 10th year of leading presentations and interactive discussions in the latest advancements in electric vertical takeoff and landing aircrafts, and the challenges that still remain. "Vibrations destroy everything," said KULR's President & COO, Keith Cochran. "Vibration issues never get better on their own; they destroy rotating components, critical electrical assemblies, induce wire chafing, cracking and fatigue of metal and composite structures, and cause loss of equipment and life. Removing vibrations increases battery efficiency resulting in longer flight time, increased payload capability and extended life of all rotating components."

08:35 EST Fortune Brands Innovations appoints David Barry CFO. succeeding Hallinan - Fortune Brands Innovations announced that David Barry has been appointed as Executive Vice President and Chief Financial Officer, effective March 2. Barry will succeed Patrick Hallinan, who is leaving the Company to pursue a new career opportunity. Hallinan will continue in his current position until March 2. "On behalf of myself, our Board of Directors and the company, I would like to thank Pat for his outstanding leadership and dedication to Fortune Brands. We are grateful for his many contributions during his six years as Chief Financial Officer, and we wish him the best as he takes on new opportunities," said management. More information about the transition will be shared at Fortune Brands' upcoming fourth quarter and full-year earnings call.

08:35 EST Imax reports second-best opening day for Chinese New Year - Imax reported its second-best opening day ever for the Chinese New Year holiday with $7M in box office across the IMAX China network on Sunday. China Film Group's "The Wandering Earth 2" - the prequel to 2019's "The Wandering Earth" - led the way with $6M. Imax opening day box office for "The Wandering Earth 2" was nearly double the opening day haul for its predecessor, and Imax locations delivered 8.5% of the film's first day gross on only 1% of screens. Imax's results were further amplified with the success of a trio of films, including "Full River Red", the period drama that marks the fifth collaboration between Imax and director Zhang Yimou.

08:34 EST Clever Leaves announces dismissal of 63 employees - On January 17, 2023, Clever Leaves' board of directors authorized a restructuring plan that is designed to improve operating margin and support the Company's growth, scale, and profitability objectives. In conjunction with its restructuring plan and wind-down in Portugal, the Company announced a collective dismissal of 63 employees associated with its Portuguese operations. Clever Leaves expects to incur total charges of approximately $19 million to $21 million in the fourth quarter of 2022 related to its operational closure in Portugal, inclusive of the following expenses: Approximately $0.7 million to $0.9 million related to severance and employee benefits; Approximately $12 million to $13 million related to real estate and equipment exit costs, consisting of lease impairment, as well as property and equipment abandonment charges; and Approximately $6 million to $7 million related to the write-off of inventories that will not be sold. Of the foregoing $19 million to $21 million in estimated charges, approximately $1.5 million to $2.0 million are expected to be cash expenditures with the balance being non-cash write-offs of prior investments. Taken together, the operational transition and workforce reduction initiatives are expected to generate approximately $7 million in savings by year-end 2023, compared to 2022.

08:33 EST Synchrony expects decline in net charge-off rate in Q3, normalization path in Q4 - Expects reserve builds generally asset-driven in FY23. Comments taken from Q4 earnings conference call.

08:32 EST Trust Stamp receives notice of allowance from U.S. Patent, Trademark Office - Trust Stamp announced that it has received a Notice of Allowance from the United States Patent Office for its Privacy-First Identity Company trademark. Trust Stamp launched its low-code Privacy-First Identity solution for banks and financial institutions in 2022 and is now seeing significant traction, with 22 banks enrolling in paid pilot programs over the past three months. "Trust Stamp's mission is to accelerate secure financial and societal inclusion, on and offline, for everyone, everywhere, by giving them the means to establish their identity using universally accessible privacy-first products and services," said Gareth Genner, CEO & Co-founder of Trust Stamp. "Our mission's emphasis on privacy resonates with multiple industries, and this trademark further emphasizes our commitment to making our mission a reality."

08:32 EST Cadrenal Therapeutics granted FDA Fast Track designation for tecarfarin - Cadrenal Therapeutics announced that the U.S. FDA has granted a Fast Track designation to tecarfarin for the prevention of systemic thromboembolism, more commonly referred to as blood clots, of cardiac origin in patients with end-stage renal disease and atrial fibrillation.

08:29 EST Wheeler REIT announces expiration, final results of exchange offer - Wheeler Real Estate Investment Trust announced the expiration and final results of its exchange offer and related solicitation of consents from the holders of the Company's Series D Cumulative Convertible Preferred Stock to certain amendments to the Company's charter that would modify the terms of the Series D Preferred Stock. The Exchange Offer expired at 11:59 p.m., New York City time, on January 20, 2023. The Company has been informed by the Exchange Agent, Computershare Inc., that as of the Expiration Date and Time, 864,391 shares of Series D Preferred Stock had been validly tendered in the Exchange Offer. Accordingly, the condition that the holders of at least 66 2/3% of the outstanding shares of Series D Preferred Stock validly tender their Series D Preferred Stock into the Exchange Offer, and not validly withdraw such Series D Preferred Stock, and consent to the Proposed Amendments, has not been satisfied as of the Expiration Date and Time. Therefore, the Series D Preferred Stock will remain outstanding with no change to its terms. No shares of Series D Preferred Stock will be exchanged by the Company for its 6.00% Subordinated Convertible Notes due 2028andcommon stock, and the shares of Series D Preferred Stock previously tendered in the Exchange Offer will be promptly returned to the tendering holders. No consideration will be paid or become payable to holders who validly tendered their shares of Series D Preferred Stock in the Exchange Offer.

08:26 EST Siyata Mobile receives order for MCPTT solution - Siyata Mobile announced it has received an order for its next-generationmission critical push-to-talk solution, which includes its SD7 device and related accessories, from a multi-billion-dollar, integrated resort and residential property development located in The Bahamas.

08:21 EST Bionano Genomics announces launch of multiple new products - Bionano Genomics announced the launch of multiple new products and advancements for its optical genome mapping, OGM, workflow that offer enhanced robustness in sample preparation, decreased turnaround time for DNA labeling and imaging, and improvements in throughput and quality metrics. The new versions of Bionano's sample prep kits, chips and instrument software address customer feedback and can improve the performance in routine higher volume genome analysis applications. Erik Holmlin, PhD, president and chief executive officer of Bionano, commented, "With these product launches we are significantly expanding the genome analysis capabilities available to the clinical and translational research communities. We look forward to seeing customers benefit from these solutions in the coming months, which we believe can reduce time-to-results and make OGM performance even better. We believe these improvements can enable greater detection of structural variants of all types associated with genetic diseases and complex disorders like cancer."

08:20 EST BIO-key announces AAC selected its PortalGuard IDaaS platform - BIO-key International announced that the Abraham Baldwin Agricultural College, ABAC, one of 26 University System of Georgia members, has selected its PortalGuard IDaaS platform. PortalGuard's cloud-based Identity as a Service, IDaaS, solution supports over 3M users, including students, faculty, staff, and administration at over 200 higher education institutions. "Universities and colleges generally want to promote an open culture which can create vulnerability to cyber attacks they're often not prepared to avoid," said Mark Cochran, President of BIO-key - PortalGuard. "BIO-key's robust PortalGuard IDaaS platform delivers a secure, flexible, and cost-effective solution to address these challenges."

08:18 EST Franklin Electric board increases quarterly dividend 15% to 22.5c per share - Franklin Electric Co., Inc. (NASDAQ: FELE) announced that its Board of Directors declared a quarterly cash dividend of 22.5c per share payable February 16, 2023, to shareholders of record on February 2, 2023. This represents a 15% increase from the prior quarterly dividend. "This dividend increase will mark the 31st consecutive year that Franklin Electric has increased its dividend, demonstrating its commitment to returning cash to shareholders and confidence in the outlook of the business," commented Gregg Sengstack, Franklin Electric's Chairperson and Chief Executive Officer.

08:17 EST Patriot Battery Metals appoints Natacha Garoute as CFO - Patriot Battery Metals announced the appointment of Natacha Garoute, LLB, CPA to the position of CFO effective today. Dusan Berka has stepped down as CFO but will remain on the Board of directors. She most recently held the position of CFO at Champion Iron Ore and was CFO and Corporate Secretary with Roxgold between 2013 and 2018.

08:16 EST Cognizant to acquire Mobica, terms not disclosed - Cognizant has entered into an agreement to acquire Mobica, an IoT software engineering services provider headquartered in Manchester, United Kingdom. Mobica's services span the full software development cycle, with core competencies in development, implementation, testing and deployment of embedded software, and a specialization in clients' strategic internal research and development projects. Upon closing of the acquisition, Cognizant will add nearly 900 people across Europe and North America, including approximately 550 engineers in Poland. The acquisition is expected to close in February 2023, subject to satisfaction of closing conditions. Financial details were not disclosed.

08:15 EST iCAD Pressure announces CFO transition, hires SVP, US commercial sales - iCAD (ICAD) announced the Board of Directors has approved the appointment of Daniel Shea, CPA, as interim Chief Financial Officer, CFO, effective immediately. The Company has launched a search for a full-time CFO, with the goal of completing that process in approximately 90 days. Also, after a search process, iCAD hired Bill Keyes as Senior Vice President, SVP, US Commercial Sales, AI. With more than 30 years of experience building, leading and advising finance functions in both private and public companies, Shea previously served as CFO at companies including Pressure Biosciences (PBIO), 4D Technologies, and Easterly Partners Group. Keyes most recently served as Chief Growth Officer at i2i Population Health and Senior Vice President, Sales and Marketing, at Connecture.

08:12 EST NuCana regains compliance with Nasdaq minimum bid price requirement - NuCana announced that it has received a written notification from the Listing Qualifications Department of the Nasdaq Stock Market informing the Company that it has regained compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5450(a)(1) and the matter is closed.

08:11 EST IO Biotech appoints Smith as General Counsel, Chief Compliance Officer - IO Biotech announced the appointment of Devin Smith as the company's first General Counsel and Chief Compliance Officer. Smith will oversee all company legal activities and provide strategic guidance and corporate governance. Smith joins IO Biotech from Yumanity Therapeutics where he served as Senior Vice President and General Counsel.

08:10 EST Clinigen divests Proleukin to Iovance Biotherapeutics for GBP 166.7M - Clinigen Limited has entered into an agreement to divest Proleukin to Iovance Biotherapeutics. Terms of the agreement include an upfront payment of GBP 166.7M, a GBP 41.7M milestone payment upon first approval of lifileucel in advanced melanoma, and double-digit Proleukin global sales royalties from Iovance to Clinigen. The transaction is expected to close in the first quarter of 2023, subject to required regulatory approvals and clearances and other customary closing conditions.

08:09 EST Catalyst Pharmaceuticals notified of ANDA filing for FIRDAPSE - Catalyst Pharmaceuticals (CPRX) announced that it has received a Paragraph IV Certification Notice Letter from Teva Pharmaceuticals (TEVA) advising that Teva had submitted an Abbreviated New Drug Application, ANDA, to the U.S. Food and Drug Administration, FDA, seeking authorization from the FDA to manufacture, use or sell a generic version of FIRDAPSE in the United States. In the Notice Letter, Teva states that it intends to market a generic version of FIRDAPSE before the expiration of Catalyst's patents listed in the FDA Orange Book covering FIRDAPSE: U.S. Patent Numbers 10,626,088; 10,793,893; 11,060,128; 11,268,128; 11,274,331; and 11,274,332. Teva's Notice Letter states that its ANDA contains a Paragraph IV Certification alleging that these patents are not valid, not enforceable, and/or will not be infringed by the commercial manufacture, use or sale of the proposed product described in Teva's ANDA submission. Under the Federal Food, Drug, and Cosmetic Act, as amended by the Drug Price Competition and Patent Term Restoration Act of 1984, as amended, Catalyst has 45 days from receipt of the Notice Letter to commence a patent infringement lawsuit in a federal district court against Teva to trigger a stay precluding FDA from approving Teva's ANDA until May 2026 or entry of judgment holding the patents invalid, unenforceable, or not infringed, whichever occurs first.

08:07 EST Rhythm Pharmaceuticals announces HRQOL improvement from Phase 3 trial in BBS - Rhythm Pharmaceuticals announced that patients with Bardet-Biedl syndrome, BBS, and obesity who participated in the company's global Phase 3 clinical trial of setmelanotide reported clinically meaningful improvements across multiple health-related quality of life, HRQOL, measures based on an analysis published in the Orphanet Journal of Rare Diseases. In total, 20 patients with BBS and obesity completed various self-reported HRQOL measures at baseline and after 52 weeks of treatment with setmelanotide, which is a precision medicine designed to re-establish MC4R pathway signaling that is approved by the U.S. Food & Drug Administration, FDA, for chronic weight management in adult and pediatric patients six years of age and older with monogenic or syndromic obesity due to BBS. For the 52-week analysis, 9 patients younger than 18 years, or their caregiver, reported a significant and clinically meaningful change in their quality of life with a mean change from baseline of +11.2 points on the Pediatric Quality of Life Inventory measure. In addition, 11 adult patients who completed the Impact of Weight on Quality of Life Questionnaire-Lite achieved a significant and clinically meaningful improvement in their weight related quality of life with a mean change from baseline of +12.0 points. IWQOL-Lite score was significantly correlated with changes in percent body weight and body mass index.

08:05 EST Centene completes divestiture of Magellan Specialty Health to Evolent Health - Centene (CNC) announced that it has completed the previously announced divestiture of Magellan Specialty Health to Evolent Health (EVH). Centene received approximately $660M in proceeds at closing, subject to adjustment in accordance with the purchase agreement, with approximately $400M paid in cash and the remainder paid in Evolent common stock. In addition, Centene will receive up to $150M in cash and Evolent common stock in 2024 if certain performance metrics are achieved.

08:05 EST Rain Oncology announces publication of Phase 1 data of milademetan - Rain Oncology announced the publication of a peer-reviewed article titled, "A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients with Advanced Liposarcoma, Solid Tumors or Lymphomas" in the Journal of Clinical Oncology. Phase 1 clinical data in the paper highlight the activity and tolerability using intermittent dosing of milademetan across a range of tumor types including dedifferentiated liposarcoma, which represented the largest proportion of patients enrolled in the study. Key Article Highlights Include: All liposarcoma patients enrolled in the Phase 1 trial exhibited the DD LPS subtype: Among DD LPS patients in the Phase 1 trial, median progression-free survival outcomes were maintained with intermittent dosing schedules compared with extended/ continuous schedules: mPFS of patients across all doses/schedules: 7.2 months; mPFS of patients with 260 mg qd 3/14 intermittent schedule: 7.4 months; mPFS of previously treated patients with 260 mg qd 3/14 intermittent schedule: 8.0 months; mPFS of treatment-naive patients in all doses/schedules: 14.6 months; Although all tested DD LPS patients had MDM2 gene amplification, mPFS in DD LPS patients did not differ by levels of key biomarkers including MDM2 or CDK4 copy number or by mRNA expression levels of MDM2, CDK4, or MDM4. The preferred intermittent dosing schedule of milademetan mitigates dose-limiting hematologic adverse events while maintaining activity, leading to: Marked reductions in occurrence and severity of grade 3/4 drug-related thrombocytopenia compared to extended/continuous schedules and Fewer dose reductions and dose interruptions compared with extended/continuous schedules. Preliminary single-agent activity with milademetan in DD LPS prompted the ongoing, randomized Phase 3 MANTRA trial, with topline data anticipated in the first quarter of 2023.

08:03 EST Leidos awarded task orders worth up to $1.5B - Leidos was recently awarded two new task orders under the IT Support Services Contract II by the Social Security Administration. The indefinite delivery/indefinite quantity, time and material task orders will provide systems and infrastructure support for the SSA's Deputy Commissioner of Systems (DCS) and the Office of Systems Operations and Hardware Engineering. Each award has a base period of performance with five one-year options and one six-month option. The awards hold a combined estimated value of $1.5B if all options are exercised.

08:02 EST Univar to acquire Turkish specialty chemicals distributor Kale Kimya, no terms - Univar Solutions announced that it has signed an agreement to acquire leading Turkish specialty chemicals distributor Kale Kimya. Terms of the transaction were not disclosed. Closing of the acquisition is subject to certain regulatory approvals and is expected to be completed within Q1 2023.

07:43 EST Midatech Pharma hires Quantuma to undertake contingency planning - The company said, "While the Company has sufficient cash resources to fund its operations until mid-March 2023 and the Board will seek to preserve its cash resources as far as practicable, it urgently requires a commitment for alternative sources of funding in advance of mid-March 2023 to be able to continue as a going concern and the Board are exploring options. There can be no guarantee that the Company will be able to find alternative sources of funding on a timely basis. If alternative funding is not available, the Directors believe that it is likely that the Company could be forced to enter into administration. The Board wishes to ensure that it is acting in the best interests of creditors and other stakeholders. Therefore, in light of today's vote at the General Meeting and its financial position, the Company has appointed Quantuma Advisory Limited, a specialist business advisory firm, to undertake contingency planning and provide advice to the Board of Directors on appropriate actions."

07:36 EST Solaris Resources reports results from metallurgical test work on Warintza - Solaris Resources reports results from metallurgical test work on its Warintza Project in southeastern Ecuador. The Company commissioned FLSmidth USA to complete comminution and metallurgical flotation test work programs. Mr. Daniel Earle, President & CEO, commented: "Warintza is blessed with simple metallurgy that readily returns high recoveries of critical minerals from standard flotation processes into high-grade concentrates free of deleterious elements. Historical testing reported high recoveries of over 90% for copper and 70% for gold; our testing has reproduced these results and established high recoveries for molybdenum of over 80% at a time when molybdenum prices recently eclipsed $30/lb due to structural supply issues in the sector." Highlights: High recoveries for copper, molybdenum and gold in rougher flotation, cleaner flotation and locked cycle testing; Low reagent dosages and short flotation times over a wide range of pH levels, and requiring only moderate to coarse grind sizes for both supergene and hypogene samples; High copper concentrate grades expected from both supergene material at 40% Cu and hypogene material at 22% Cu with both concentrates containing in excess of 1 g/t Au ; High molybdenum concentrate grades expected to meet or exceed 51% Mo independent of feed type given excellent liberation of coarse grained molybdenite; For context, the Warintza Mineral Resource Estimate includes a molybdenum byproduct estimate containing 150 kt Mo grading 0.03% Mo and 130 kt Mo grading 0.01% Mo (Inferred), in addition to gold; Concentrates free of deleterious elements, with no significant values of arsenic, antimony, bismuth or mercury; Optimization testing with larger sample sizes planned for hypogene material aimed at further increasing recoveries.

07:29 EST Ainos, Tah-An sign MOU to explore manufacture of VELDONA - Ainos announced that it has signed a Memorandum of Understanding with Taiwanese animal drug manufacturer Tah-An Chemical & Pharmaceutical. Ainos and Tah-An intend to jointly explore the feasibility of manufacturing an animal investigational new drug based on the Company's VELDONA formulation. Ainos plans to begin animal clinical trials for potential veterinary applications of VELDONA in the first quarter of 2023. Tah-An is proposed as the contract manufacturer of the new drug candidates and Ainos plans to contribute technical assistance. The companies are currently engaged in talks to establish a formal contract based on the MoU terms.

07:25 EST Unicycive Therapeutics announces acceptance of abstracts at NKF meetings - Unicycive Therapeutics announced that three abstracts have been accepted for presentation at the National Kidney Foundation's upcoming Spring Clinical Meetings taking place in Austin, Texas from April 11-15, 2023. The following data will be presented at the NKF's Spring Clinical Meeting: Results from three pre-clinical studies of UNI-494, evaluating the risk of drug/drug interactions will be presented in a poster titled, "In Vitro Drug Interaction Studies of UNI-494 Indicate Low Risk of Drug-Drug Interactions." Efficacy data from a study of UNI-494 in a bilateral renal ischemia perfusion model will be presented in a poster titled, "UNI-494 Lowers Urine 2-microglobulin in Rats." Outcomes from a study that evaluated the medication weight of various phosphate binders to bind 1 gram of phosphorus will be presented in a poster titled "Binder Weight to Bind 1 Gram of Phosphate."

07:21 EST International Petroleum announces results of normal course issuer bid - International Petroleum Corporation announced that IPC repurchased a total of 167,500 IPC common shares during the period of January 16 to 20, 2023 under IPC's normal course issuer bid / share repurchase program. IPC's NCIB, announced on December 1, 2022, is being implemented in accordance with the Market Abuse Regulation No 596/2014 and Commission Delegated Regulation No 2016/1052 and the applicable rules and policies of the Toronto Stock Exchange and Nasdaq Stockholm and applicable Canadian and Swedish securities laws. During the period of January 16 to 20, 2023, IPC repurchased a total of 120,000 IPC common shares on Nasdaq Stockholm. All of these share repurchases were carried out by Pareto Securities AB on behalf of IPC.

07:17 EST incredibles launches 50 Shades of Grape gummy in Illinois - incredibles, a cannabis brand from Green Thumb Industries, announced that it has launched its new, limited-edition 50 Shades of Grape gummy in the Illinois market. Made with pure THC distillate, the gummies feature a cannabinoid ratio of 50 mg THC / 50 mg CBD per pack and 5 mg THC / 5 mg CBD per gummy.

07:16 EST Perella Weinberg Partners announces new partners - Perella Weinberg Partners announced the promotion of two Managing Directors to Partners of the Firm, effective January 1, 2023: Anthony Giuliano - New York; Cory Hill - Los Angeles.

07:15 EST Canacol Energy announces discoveries at Dividivi1, Saxofon 1, Chimela 1 - Canacol Energy provide details on the following three discoveries, as well as information concerning its near term drilling programs. Saxofon 1 - Encounters 338 feet of gross gas pay within the Porquero and CDO reservoirs: The Corporation commenced the drilling of the Saxofon 1 exploration well on December 2, 2022 on its 100% operated VIM5 Exploration and Production contract located in the Lower Magdalena Basin. The well reached a total depth of 9,416 feet measured depth on January 7, 2023 and encountered a gross gas column of 290 feet true vertical depth within the Porquero sandstone reservoir between depths of 4,385 and 4,675 ft md, and a gross gas column of 48 ft tvd within the primary Cienaga de Oro sandstone reservoir between 7,560 and 7,608 ft md. The gas bearing reservoirs encountered within the Porquero sandstone display average porosity of 26 %, while those within the CDO sandstone display average porosity of 16 %. The well is currently being cased, and the Corporation is planning to mobilize a workover rig to complete and test the CDO. The development plan for Saxofon will include the drilling of additional appraisal and development wells once a new 3D seismic survey has been acquired over that area of the block in late 2023. The Corporation will provide production test results when they become available. Dividivi 1 - Encounters 89 feet of gross gas pay within the CDO and Cicuco reservoirs: The Corporation commenced the drilling of the Dividivi 1 exploration well on December 20, 2022 on its 100% operated VIM33 E&P contract located in the Lower Magdalena Basin. The well reached a total depth of 4,692 ft md on January 2, 2023 and encountered a gross gas column of 89 ft tvd within the primary CDO sandstone and Cicuco limestone reservoirs between depths of 2,184 and 2,273 ft md. The gas bearing reservoirs have average porosity of 27 %. The Corporation is currently executing a flow test of the well in order to formulate a commercial development plan for the discovery. The discovery is located approximately 35 kilometers to the west of the TGI gas pipeline which currently has approximately 260 MMscfpd of spare transportation capacity into the interior of Colombia. The Corporation will provide production test results when they become available. Chimela 1 - Encounters 85 feet of net oil and gas pay within the Lisama reservoir: The Corporation commenced the drilling of the Chimela 1 exploration well on November 13, 2022 on its 100% operated VMM45 E&P contract located in the Middle Magdalena Basin. The well reached a total depth of 14,101 ft md on December 16, 2022, and encountered multiple zones of oil and gas pay within the primary Upper Lisama and Basal Lisama sandstone reservoirs between depths of 12,410 and 13,694 ft md. The oil bearing reservoirs encountered within the Basal Lisama were encountered between 13,004 and 13,694 ft md with individual oil filled sands between 8 and 20 ft tvd in thickness, with average porosity of 14 %. The gas bearing reservoir within the Upper Lisama is 9 ft tvd thick, with an average porosity of 10 %. The Corporation is currently demobilizing the drilling rig and is preparing to mobilize a workover rig to complete and production test the well and will provide results when they become available. Natilla 1 - Sidetracking: The Corporation spud the Natilla 1 exploration well located on its 50% operated working interest SSJN 7 E&P contract on December 1, 2022. Natilla 1 is targeting gas bearing sandstones within the CDO and Porquero sandstone reservoirs. The well drilled to a depth of 11,848 ft md within the Porquero sandstone interval, the secondary target of the well, prior to encountering drilling related problems. The well is currently being sidetracked and the Corporation anticipates to reach planned total depth of 16,609 ft MD within the primary CDO sandstone target within 6 weeks. The Corporation plans to spud the Lulo 1 exploration well located on its 100% working operated interest Esperanza Exploration and Exploitation contract in mid March 2023. The Lulo 1 well is located less than 1 kilometer to the east of the Jobo production facility and is targeting gas bearing sandstones of the CDO sandstone reservoir. The well is anticipated to take 4 weeks to drill and complete.

07:14 EST Vitalhub acquires Coyote Software for $2.37M - Vitalhub announces that it has acquired Coyote Software Corporation, a company incorporated and existing under the laws of the Province of Ontario. Coyote specializes in tailored software solutions that streamline the workflows of health and social service organizations. VitalHub acquired Coyote from its shareholders for a purchase price of $2,373,528. The purchase price was satisfied by a cash payment of $2,265,5281, a portion of which will be held in escrow for a six month period following closing of the Acquisition, and the delivery of 38,163 common shares of VitalHub, at a deemed price of $2.83 per share, to the principal shareholder of Coyote. These shares are subject to a four month hold from their date of issuance. "With this Acquisition, we are excited to expand upon our robust suite of offerings specifically servicing the Canadian marketplace, together with our BCare, TREAT, Clarity, and Roxy solutions. We look forward to welcoming Coyote's team members and CaseWORKS solution to the Company," said Dan Matlow, CEO of VitalHub Corp. "We currently have over 250 customers using our health and social service solutions across Canada, providing further ratification of our leadership in this sector and the strong market demand for our products. This acquisition serves to further advance our strategic M&A objectives, bringing new product synergies that can be cross sold into our existing install base, alongside an existing strong base of recurring revenue customers."

07:12 EST Spotify: Alex Norstrom, Gustav Soderstrom appointed co-presidents

07:12 EST Spotify's Chief Content & Advertising Business Officer Dawn Ostroff to leave

07:11 EST Agrify 'confident' in ability ro withstand 'challenging circumstances' - "Over the past few years, Agrify has fortified its position as one of the leading solution providers in the cannabis industry, offering customers a full suite of highly compelling products and services across cultivation and extraction," said Raymond Chang, CEO. "However, like many organizations in our industry and within the broader business landscape, we continue to encounter various headwinds that have necessitated significant adjustments to our short-term operating plan. Consequently, we have taken steps to create more stability during these uncertain times by better aligning our resources with the most attractive growth opportunities currently at our disposal, optimizing our sales strategy, and ensuring we have the right team in place to execute on our goals. As we forge ahead, we are confident in our collective ability to withstand these challenging circumstances and pursue a more suitable path for growth. We believe the plan we are carrying out will enable us to become cash flow positive by the end of the year and support the creation of greater value for our shareholders, customers, and employees. While some of the dynamics in the current macro environment have undoubtedly impeded progress for all, we believe the cannabis industry continues to offer substantial long-term upside, with robust global growth expected in the coming years. We have worked diligently to establish ourselves as a leading brand across cultivation and extraction, and we remain undeterred in our quest to become the world's most innovative end-to-end solution provider in the cannabis industry, offering a comprehensive ecosystem of products and services to help our customers succeed at any stage of growth."

07:11 EST Spotify announces reduction in employee base by about 6%

07:09 EST Agrify focused on growing cultivation business - Agrify's diversified mix of products and services gives the Company flexibility to adjust its sales approach to capitalize on the market opportunities or sales channels that are most attractive at a given point in time. The Company is currently focused on growing its cultivation business by helping its existing Agrify Total Turn-Key Solution customers bring their facilities online, driving additional sales through its Rapid Deployment Pack program, and making a concerted effort to successfully capture market share in the academic and pharmaceutical research verticals. The Company expects to have several more customer cultivation facilities coming online in 2023, including some highly anticipated Agrify TTK Solution customer sites. Once these new Agrify TTK Solution facilities are fully operational, the underlying business model for this program, which includes high-margin recurring revenue streams, should be instrumental in creating substantial long-term value for the Company's shareholders. Despite the attractive returns the Company expects from its existing Agrify TTK Solution customers, Agrify will temporarily wait to pursue new opportunities that require construction financing until the market stabilizes, as those engagements are capital intensive upfront with a deferred payback period. This should significantly reduce the cash burn of the Company. In the interim, the Company expects to shift its resources to pursue other more appealing growth initiatives such as the RDP program and the academic and pharmaceutical research verticals. Agrify's RDP program was established to make it easier for a broader range of customers, both domestically and abroad, to access Agrify's award-winning cultivation technology. Featuring Agrify's flagship Vertical Farming Units in a prepackaged, self-contained, and quick-to-deploy format, the thoughtfully designed and engineered RDPs offer an accelerated path to production, cash flow, and profitability for customers. By removing certain barriers and points of friction with the RDPs, Agrify is able to provide customers who have properly equipped facilities best-in-class cultivation capabilities in potentially as little as 90 days. Once installed, the modular nature of the RDPs allows for seamless expansion opportunities, enabling customers the flexibility to grow and scale. In addition to the general expansion of the RDP program, the Company is looking to further introduce its fully integrated cultivation solution into the historically underserved academic and pharmaceutical research channels. In the past, progress in these channels had been stifled by stringent government restrictions, but the recent directive by the Biden administration to review the classification of cannabis under federal law and Congress' enactment of the Medical Marijuana and Cannabidiol Research Expansion Act have opened up a potentially lucrative opportunity to support these budding verticals, which are aiding both the advancement and acceptance of cannabis. This has led to an influx of educational programs and research grants related to cannabis. In 2023, Agrify hopes to be able to begin serving the needs of an increasing number of universities, research institutions, and pharmaceutical companies as they look to push the boundaries within the field of cannabis science and bring higher quality products to the market. The Company's extraction business, which consists of Precision Extraction Solutions, PurePressure, Lab Society, and Cascade Sciences with leading products across hydrocarbon, ethanol, solventless, post-processing, and lab equipment, has also made certain adjustments to meet the shift in the market toward small licenses as compared to larger vertical licenses. In the past two years, many licenses awarded were smaller and limited licenses focused on social equity and diversity, including within states such as Illinois, New York, Connecticut, Virginia, and Massachusetts. Agrify has streamlined its expansive extraction product portfolio to better support its sales efforts in 2023 and has also continued to innovate with several new products scheduled to launch this year. Additionally, the Company has amassed an extensive customer database it intends to leverage for compelling cross-selling and upselling opportunities.

07:07 EST Regenxbio announces Phase 1/2 trial of RGX-202 in Duchenne - Regenxbio announced that the Phase 1/2 AFFINITY Duchenne trial of RGX-202 for the treatment of Duchenne muscular dystrophy is now active and recruiting patients. RGX-202 is designed to deliver a transgene for a novel microdystrophin protein that includes the functional elements of the C-Terminal domain found in naturally occurring dystrophin. RGX-202 uses Regenxbio's proprietary NAV AAV8 vector. The trial is an open-label dose evaluation and dose expansion clinical trial to evaluate the safety, tolerability and clinical efficacy of a one-time intravenous dose of RGX-202 in patients with Duchenne.

07:06 EST Hestia nominates 7 candidates for election to Pitney Bowes board - Hestia Capital Management , which is the third largest stockholder of Pitney Bowes, and has a beneficial ownership position of approximately 7.2% of the Company's outstanding shares announced that it has nominated seven highly qualified and independent candidates for election to the Company's nine-member Board of Directors at the Company's 2023 Annual Meeting of Stockholders . In addition, Hestia released a presentation that details a sampling of current leadership's failings that have led to significant stockholder value destruction. Kurt Wolf, Founder and Chief Investment Officer of Hestia, commented: "Hestia has purposefully recruited a well-rounded slate of director candidates that possesses capital allocation acumen, corporate governance expertise, relevant sector backgrounds, operating and transaction experience and ownership perspectives - all of which are needed at Pitney Bowes. Our slate also has deep knowledge of the Company's balance sheet, business segments, market opportunities and secular headwinds. As a result of their experience and insight, our candidates have already been able to identify steps for turning around the Company and quickly repairing its severely damaged credit rating. We look forward to announcing an interim Chief Executive Officer candidate, issuing a 100-day transition plan and sharing a detailed value creation strategy prior to the upcoming Annual Meeting.

07:06 EST Agrify announces strategic plan to foster long-term growth - Agrify Corporation announced it is actively taking steps to better align its resources and growth plan with the current operating environment, measures that the Company believes could put it in a position to be cash flow positive by the end of 2023. The company said, "Agrify, which offers both domestic and international customers one of the most comprehensive portfolios of cultivation and extraction solutions, has responded to the turbulence facing the entire cannabis industry by developing and instituting a plan to provide stability during the market downturn as well as a sustainable path forward. The plan primarily consists of reducing certain costs and leveraging various cost synergies to achieve new operational efficiencies, growing the top-line revenue through targeted sales efforts in the most attractive channels, and assembling the best leadership and talent in the industry."

07:05 EST TScan Therapeutics announces FDA clearance of three IND applications - TScan Therapeutics announced that the U.S. Food and Drug Administration, FDA, has cleared its investigational new drug, IND, applications for T-Plex, TSC-204-A0201, and TSC-204-C0702. T-Plex will now serve as the primary IND for TScan's solid tumor program, enabling customized combinations of TCR-Ts to be administered to patients based on the targets and HLAs expressed in their tumors. The specific TCRs for each patient will be chosen from the Company's ImmunoBank, consisting of high-affinity, naturally occurring TCRs that recognize a variety of prevalent cancer-specific targets and are associated with various common HLA types. Each unique TCR-T will be filed as a secondary IND and will reference the primary T-Plex IND. In addition to the T-Plex IND, TScan filed secondary INDs for two initial TCR-T products, TSC-204-A0201 and TSC-204-C0702, that target melanoma-associated antigen 1 on HLA types A*02:01 and C*07:02. TScan believes that TSC-204-C0702 is the first clinical program in MAGE-A1 for an HLA type other than A*02:01. With these INDs cleared, TScan is now working to open a multicenter Phase 1 clinical trial to establish the safety, preliminary efficacy, and feasibility of repeat dosing of multiplexed TCR-T. David P. Southwell, President and Chief Executive Officer continued: "Today marks the first three IND clearances for our solid tumor program and further validates the use of our proprietary platform to identify therapeutic TCRs suitable for clinical development. With the FDA clearance of T-Plex, along with two MAGE-targeting TCRs, we are now one step closer to bringing bespoke cell therapies to patients. We are continuing to build our ImmunoBank, with four more IND filings anticipated in 2023."

07:05 EST Ritchie Bros., IAA announce amended merger agreement - Ritchie Bros. (RBA) and IAA, Inc. (IAA) announced that they have amended the terms of their previously announced merger agreement, pursuant to which Ritchie Bros. will acquire IAA in a stock and cash transaction. The amended agreement, which delivers enhanced value to Ritchie Bros. shareholders and increased cash consideration to IAA shareholders, has been unanimously approved by each company's Board of Directors. Under the terms of the amended agreement, IAA shareholders will receive $12.801 per share in cash and 0.5252 common shares of Ritchie Bros. for each share of IAA common stock they own. The change in consideration mix represents a shift in the cash/stock mix to approximately 29% cash/71% stock from the previous mix of 22% cash/78% stock. Additionally, the Ritchie Bros. Board of Directors announced that it expects to approve the issuance of a one-time special dividend to Ritchie Bros. shareholders in the amount of $1.08 per common share, which will be payable to holders of record as of a pre-closing record date to be determined with the consent of the Toronto Stock Exchange and contingent on the closing of the IAA transaction. Pursuant to a mutual cooperation agreement reached between IAA and Ancora, Tim O'Day, a seasoned industry executive and operator and the current President and CEO of Boyd Group Services Inc., is expected to be appointed to the Ritchie Bros. Board of Directors upon the closing of the transaction. He will be one of the four IAA board designees, subject to satisfactory completion of customary vetting and onboarding matters. Under the terms, Ancora has agreed to vote its shares, representing approximately 4% of IAA's voting power, in favor of the transaction.

07:02 EST Ritchie Bros. announces $500M investment from Starboard Value - Ritchie Bros. announced that it has entered into a securities purchase agreement with Starboard Value LP and certain of its affiliates pursuant to which Starboard will make a concurrent $485M convertible preferred equity and $15M common share investment in Ritchie Bros. In connection with the investment, Starboard CEO Jeffrey Smith will be appointed to the Ritchie Bros. Board of Directors effective following the later of the required approvals by Ritchie Bros. shareholders and IAA shareholders in connection with the company's pending acquisition of IAA, Inc. Under the terms of the securities purchase agreement, Starboard has agreed to purchase $485 million of newly issuable senior preferred shares of Ritchie Bros., convertible into common shares with an initial conversion price of $73.00 per share, representing a premium of approximately 23% over Ritchie Bros.' volume-weighted average price over the 10 trading day period ending on January 20, 2023. The preferred shares will carry an initial 5.5% preferred dividend, which is payable in cash or in shares at the company's option, and will also be entitled to participate on an as-converted basis in the company's regular quarterly common share dividends. Concurrently, Starboard has also agreed to purchase approximately $15 million of common shares in Ritchie Bros. at a purchase price of approximately $59.72 per share. The shares underlying Starboard's investment will not be voted at the Special Meeting of Ritchie Bros. Shareholders to be held with respect to the IAA transaction. In the event that the merger between Ritchie Bros. and IAA is terminated, the company will have the right to redeem the preferred shares at a redemption price of 102% of par plus accrued and unpaid dividends.

07:00 EST Kosmos' floating vessel for GTA liquified natural gas project begins voyage - Kosmos Energy announced that the floating production, storage and offloading vessel for the Greater Tortue Ahmeyim liquefied natural gas project has departed the COSCO shipyard in China to commence its voyage via Singapore to the project site on the maritime border of Mauritania and Senegal. The vessel is expected to arrive in Q2.

06:58 EST Asensus Surgical receives CE mark for expanded machine vision capabilities - Asensus Surgical has received CE Mark for an expansion of machine vision capabilities on the previously cleared Intelligent Surgical Unit. With this CE Marking, the expanded ISU capabilities are now commercially available across all of the company's key geographies, including the EU, Japan, and the U.S. In addition, this approval included a review of the Senhance Surgical System platform. The Senhance Surgical System is powered by the Intelligent Surgical Unit.

06:55 EST Xylem to acquire Evoqua Water in $7.5B all-stock transaction

06:30 EST BiondVax's inhaled NanoAb for COVID-19 shows efficacy in preclinical study - BiondVax announced additional results in a preclinical proof-of-concept study of its inhaled NanoAb COVID-19 drug. The study compared weight loss in two groups of hamsters. Hamsters administered a mid-sized 0.66mg dose of the NanoAb three hours prior to infection experienced no significant weight loss over the six-day trial, whereas the untreated control group's weight declined 12% on average, a highly statistically significant difference. These prophylactic results follow previously reported data from the same study indicating that compared to the control group, hamsters treated with a 2mg dose of BiondVax's inhaled NanoAb one day after infection had negligible SARS-CoV-2 viral titers in their lungs, and experienced a milder and shorter illness in comparison to the placebo group that had at least 30-times higher viral titers in their lungs at the end of the trial. Lung histopathology revealed that therapeutic inhalation of NanoAbs reduced damage to alveoli, pulmonary vessels, and the conductive system. This preclinical trial is continuing with additional arms testing lower therapeutic doses. The study will also evaluate safety parameters. In 2023, BiondVax is expected to conduct a preclinical toxicity study to assess safety as required by regulatory authorities for approval of human clinical trials. The company is also expected to scale up its manufacturing processes to produce the NanoAbs for the first-in-human Phase 1/2a clinical trial, planned for 4Q23.

06:06 EST MannKind says clofazimine inhalation suspension to advance to Phase 2/3 study - MannKind announced clofazimine inhalation suspension will advance to an adaptive Phase 2/3 study. Additionally, a paper has been published in the American Society for Microbiology journal Antimicrobial Agents and Chemotherapy examining the potential for treatment of nontuberculous mycobacterial infection through direct delivery of inhaled clofazimine to the lungs, overcoming the systemic toxicity witnessed in oral treatments.

06:03 EST Synchrony sees FY23 NIM 15%-15.25% - Sees FY23 loan receivables growth 8%-10%. Sees payment rate moderation expected to continue, remaining above pre-pandemic levels during 2023. Sees FY23 net charge-offs 4.75%-5%. Net Charge-Offs not expected to reach pre-pandemic levels on an annual basis until 2024 unless significant changes in macroeconomic environment develop. Sees FY23 RSA/average loan receivables 4%-4.25% and operating expenses $1.125B per quarter. The company expects to manage expenses to deliver positive operating leverage for the full year.

05:20 EST Sigma Lithium starts processing plant commissioning, reports leadership changes - Sigma Lithium announced initiation of commissioning of its dense medium separation processing plant, one month ahead of schedule. It also announces certain leadership changes. Brian Talbot will continue to lead operations as COO of Sigma Lithium. Talbot has been working with the company since 2021, leading the operating team on site playing a role in the execution of project commissioning. He also serves on the company's Technical Committee. Ana Cabral-Gardner, previously co-CEO, continues as CEO of Sigma Lithium. She will also continue as co-chair of the company's board of directors. As part of the transition, Gary Litwack, currently Sigma Lithium's lead independent board director, has been appointed non-executive co-chair of the board. Further, in preparation for evolving financial reporting responsibilities as the company transitions from developer to producer, Rodrigo Menck, who joined the company in 2022, has been named CFO of Sigma Lithium. Felipe Peres, former CFO, will continue to work closely with the finance team in the capacity of senior advisor to the company. Menck has roughly 30 years of experience in finance and capital markets. He has spent the last 15 years leading finance functions for large corporations, including most recently with Nexa Resources. Calvyn Gardner, who had been co-CEO and co-chair of the board, will remain on the board.

05:07 EST Hutchmed licenses fruquintinib to Takeda Pharmaceutical for up to $1.13B - Hutchmed (HCM) announced that its subsidiary, Hutchmed Limited, has entered into an exclusive license agreement with a subsidiary of Takeda Pharmaceutical (TAK) to further the global development, commercialization and manufacturing of fruquintinib outside of mainland China, Hong Kong and Macau, where it is marketed by Hutchmed. Hutchmed Limited will receive up to $1.13B including $400 million upfront on closing as well as potential regulatory, development and commercial sales milestone payments, plus royalties on net sales. Fruquintinib is a highly selective and potent inhibitor of vascular endothelial growth factor receptors -1, -2 and -3. Fruquintinib is orally administered and has the potential to be used across subtypes of metastatic colorectal cancer, regardless of biomarker status.